Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Vasospastic angina Indication Strategy Report 2026: ROCK2, Trials and Deals
23 July 2026
2026 Vasospastic angina strategy: epidemiology, ROCK2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Coronary microvascular dysfunction Indication Strategy Report 2026: Endothelin receptor A, Trials and Deals
23 July 2026
2026 Coronary microvascular dysfunction strategy: epidemiology, Endothelin receptor A biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Constrictive pericarditis Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Constrictive pericarditis strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Recurrent pericarditis Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Recurrent pericarditis strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Acute pericarditis Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Acute pericarditis strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Myocarditis Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Myocarditis strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Peripartum cardiomyopathy Indication Strategy Report 2026: Prolactin, Trials and Deals
23 July 2026
2026 Peripartum cardiomyopathy strategy: epidemiology, Prolactin biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Restrictive cardiomyopathy Indication Strategy Report 2026: MYH7, Trials and Deals
23 July 2026
2026 Restrictive cardiomyopathy strategy: epidemiology, MYH7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Left ventricular noncompaction Indication Strategy Report 2026: MYH7, Trials and Deals
23 July 2026
2026 Left ventricular noncompaction strategy: epidemiology, MYH7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Sinus node dysfunction Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Sinus node dysfunction strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Atrioventricular block Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Atrioventricular block strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Short QT syndrome Indication Strategy Report 2026: KCNH2, Trials and Deals
23 July 2026
2026 Short QT syndrome strategy: epidemiology, KCNH2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…